22. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises about 110mM sodium chloride and about 20mM histidine.

23. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration about once per week.

24. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration daily.

25. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration at a dosage of about 0.5 mg/mL to about 200 mg/mL.

26. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration at a dosage of about 10 mg/mL to about 50 mg/mL.

27. A method of treating diabetes comprising administering a pharmaceutical composition for providing sustained glycemic control, comprising an effective amount of a protein comprising an insulin amino acid sequence and an amino acid sequence providing a sustained release from an injection site, and pharmaceutical excipients to achieve sustained release to a patient in need thereof.

28. The method of claim 27, wherein the patient has type 1 diabetes.

29. The method of claim 27, wherein the patient has type 2 diabetes.

30. The method of claim 27, wherein the pharmaceutical composition is administered at a frequency of from 1 to about 30 times per month.

31. The method of claim 27, wherein the pharmaceutical composition is administered about weekly.

32. The method of claim 27, wherein the pharmaceutical composition is administered two or three times per week.

33. The method of claim 27, wherein the pharmaceutical composition is administered about daily.

34. The method of claim 27, wherein the pharmaceutical composition is administered subcutaneously.

22. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises about 110mM sodium chloride and about 20mM histidine.

23. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration about once per week.

24. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration daily.

25. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration at a dosage of about 0.5 mg/mL to about 200 mg/mL.

26. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for administration at a dosage of about 10 mg/mL to about 50 mg/mL.

27. The use of a pharmaceutical composition in the manufacture of a medicament for the treatment of diabetes, wherein the pharmaceutical composition comprises an effective amount of a protein comprising an insulin amino acid sequence and an amino acid sequence providing a sustained release from an injection site, and pharmaceutical excipients to achieve sustained release.

28. The use of claim 27, wherein the diabetes is type 1 diabetes.

29. The use of claim 27, wherein the diabetes is type 2 diabetes.

30. The method of claim 27, wherein the pharmaceutical composition is administered at a frequency of from 1 to about 30 times per month.

31. The method of claim 27, wherein the pharmaceutical composition is administered about weekly.

32. The method of claim 27, wherein the pharmaceutical composition is administered two or three times per week.

33. The method of claim 27, wherein the pharmaceutical composition is administered about daily.

34. The method of claim 27, wherein the pharmaceutical composition is administered subcutaneously.